SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company engaged in the development and worldwide commercialization of cytisinicline for the smoking cessation and nicotine addiction, announcing today announced its participation in the Spring Into Action Best Ideas virtual investor conference. The conference takes place virtually from May 16-20, 2022. Details to access the presentation are as follows:

Spring to Action Virtual Conference
When: Monday, May 16, 2022
Time: 1:00 p.m. EDT
Event: Presentation
To register for the conference, click HERE.

For more information on Achieve, visit https://ir.achievelifesciences.com

About Achieve and Cytisinicline
Smoking is currently the leading cause of preventable death, responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States each year.^1.2 More than 87% of lung cancer deaths, 61% of all lung disease deaths, and 32% of all coronary heart disease deaths are attributable to smoking and exposure to second-hand smoke.² Achieve’s goal is to combat the global epidemic of tobacco use and nicotine addiction through the development and commercialization of cytisinicline.

Cytisinicline is a plant-derived alkaloid with high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid smoking cessation by interacting with nicotine receptors in the brain reducing the severity of nicotine withdrawal symptoms and reducing the reward and satisfaction associated with smoking.

Cytisinicline is an investigational product candidate under development for the treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve, visit www.achievelifesciences.com.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of development cytisinicline clinical, data results and marketing. activities, the potential size of the cytisinicline market, the potential benefits, safety and tolerability of cytisinicline, the ability to discover and develop new uses for cytisinicline, including, but not limited to, in as an e-cigarette cessation product, the development and effectiveness of new treatments, and the intention to submit cytisinicline to the FDA for approval. All statements other than statements of historical fact are statements that could be considered forward-looking statements. Achieve may not achieve its product development plans or objectives in a timely manner, if at all, or otherwise achieve its intentions or meet its expectations or projections disclosed in such forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among other things, the risk that cytisinicline may not demonstrate hypothetical or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully marketed; the risk that new developments in the smoking cessation landscape may require changes in business strategy or clinical development plans; the risk that Achieve’s intellectual property may not be adequately protected; general commercial and economic conditions; risks related to the impact on our business of Russian military action in Ukraine; risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises and other factors described in the risk factors set forth in Achieve’s filings with the Securities and Exchange Commission from time other, including Achieve’s annual reports on Form 10-K and quarterly reports on Form 10-Q. Achieve undertakes no obligation to update any forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, except as may be required by applicable.

Investor Relations
rich rooster
[email protected]
(404) 736-3838

Media Contact
Glenn Silver
[email protected]
(646) 871-8485

References
¹ World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
² US Department of Health and Human Services. The health consequences of smoking – 50 years of progress. A report of the Surgeon General, 2014.